Please assess the completion status of the following clinical trial:

Trial Title: Single Dose FSH-GEX™ in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~1. Female subjects from 18-40 years of age.~2. Subjects must be in good health.~3. Subjects must be willing to use additional non-hormonal contraception~4. Subjects must have used a combined oral contraceptive (COC) for at least one cycle.~5. Vital signs which are within the following ranges at baseline measurements: systolic blood pressure of 90-140 mmHg, diastolic blood pressure of 50-90 mmHg and pulse rate of 40 - 100 bpm.~6. Subjects must have a body weight of minimally 50.0 kg with a BMI between 18.0 and 29.0 kg/m\^2 at baseline measurements.~7. Able to provide written informed consent prior to study participation.~8. Able to communicate well with the investigator and to understand and comply with the requirements of the study.~Exclusion Criteria:~1. Smokers of more than 10 cigarettes per day.~2. Average daily intake of more than 3 units of alcohol per day or an average weekly intake of more than 21 units alcohol.~3. Use of any prescription drug or ove the counter medication from screening until the end-of-study visit, without prior approval of the investigator.~4. Any drugs thay may reduce the effectiveness of COC from screening until the end-of-study visit.~5. Any follicle-stimulating hormone (FSH) preparation within 90 days prior to screening.~6. Administration of any investigational product or use of any investigational device within 30 days prior to screening.~7. Donation or loss of 500 mL or more blood within 90 days prior to first FSH-GEX™ dosing.~8. History of acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease, treated or not treated).~9. History of allergies for drugs, seafood, nuts, eggs, wasp-stings; history of atopic allergy (asthma, urticaria, eczematous dermatitis). A known hypersensitivity to any of the study drugs.~10. Any surgical or medical condition which might alter the absorption, distribution, metabolism, or excretion of drugs or which may jeopardize the subject in case of participation in the study.~11. History or presence of any malignancy.~12. Determined or suspected pregnancy.~13. Breast feeding women.~14. History of (or current) endocrine abnormalities.~15. Contraindication for the use of oral contraceptives.~16. Contraindication for the use of follitropin alfa, FSH or any of the excipients (hypersensitivity to follitropin alfa, FSH or any of the excipients; tumors of the hypothalamus or the pituitary gland; ovarian enlargement or cyst not due to polycystic ovarian disease; gynecological bleeding of unknown origin; ovarian, uterine, or mammary carcinoma).~17. Porphyria or family history of porphyria.~18. History of ovarian surgery.~19. Any ovarian or abdominal abnormality that would interfere with adequate ultrasound investigation.~20. An abnormal cervical smear.~21. History or presence of an immune-compromising disease, or a positive human immunodeficiency virus (HIV) test result in the past or at the screening visit.~22. History of Hepatitis B or C, or a positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result at the screening visit.~23. History of drug or alcohol abuse within the 12 months prior to the screening visit or evidence of such abuse.~24. Planned surgery or hospitalization during the period of the study.~25. Concurrent participation or participation within 30 days before screening in another clinical trial, or participation in more than 3 clinical studies within 12 months, prior to the expected date of enrolment into the study.~26. Injection of one or more doses of any depot contraceptive drug /drug combination or hormonal implants \<= 10 months prior to screening.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- FSH-GEX 25 IU (Type: EXPERIMENTAL): 25 IU single dose
- FSH-GEX 75 IU (Type: EXPERIMENTAL): 75 IU single dose
- FSH-GEX 150 IU (Type: EXPERIMENTAL): 150 IU single dose
- FSH-GEX 300 IU (Type: EXPERIMENTAL): 300 IU single dose
- Gonal-f (Type: ACTIVE_COMPARATOR): 150 IU single dose
- Bravelle (Type: ACTIVE_COMPARATOR): 150 IU single dose
- Placebo (Type: PLACEBO_COMPARATOR): single dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete